The use of dual antiplatelet therapy (a P2Y12 inhibitor plus aspirin) after percutaneous coronary intervention (PCI) reduces the risk of ischemic or atherothrombotic events, including stent thrombosis, recurrent myocardial infarction, and cardiovascular death. Approximately 5 to 7% of patients with…